The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection
Hepatology2016Vol. 66(2), pp. 371–378
Citations Over TimeTop 1% of 2016 papers
William F. Balistreri, Karen F. Murray, Philip Rosenthal, Sanjay Bansal, Chuan‐Hao Lin, Kathryn Kersey, Benedetta Massetto, Yanni Zhu, Bittoo Kanwar, Polina German, Evguenia S. Svarovskaia, Diana M. Brainard, Jessica Wen, Regino P. González‐Peralta, Maureen M. Jonas, Kathleen B. Schwarz
Abstract
Ledipasvir-sofosbuvir was highly effective at treating adolescents with chronic HCV genotype 1 infection; the dose of ledipasvir-sofosbuvir currently used in adults was well tolerated in adolescents and had an appropriate pharmacokinetic profile. (Hepatology 2017;66:371-378).
Related Papers
- → Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients(2016)7 cited
- → Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual(2016)3 cited
- → Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment(2015)4 cited
- → Ledipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV(2015)
- [Peruvian experience in the treatment of chronic hepatites C with the new direct acting antiviral drugs].(2020)